Absence of hepatitis delta infection in a large rural HIV cohort in Tanzania

dc.contributor.authorWinter, Annja
dc.contributor.authorLetang, Emilio
dc.contributor.authorKalinjuma, Aneth Vedastus
dc.contributor.authorKimera, Namvua
dc.contributor.authorNtamatungiro, Alex J.
dc.contributor.authorGlass, Tracy R.
dc.contributor.authorMoradpour, Darius
dc.contributor.authorSahli, Roland
dc.contributor.authorLe Gal, Frédéric
dc.contributor.authorFurrer, Hansjakob
dc.contributor.authorWandeler, Gilles
dc.contributor.authorKIULARCO Study Group
dc.date.accessioned2016-05-19T11:05:01Z
dc.date.available2016-05-19T11:05:01Z
dc.date.issued2016-05
dc.date.updated2016-05-10T15:02:08Z
dc.description.abstractOBJECTIVES: The epidemiological and clinical determinants of hepatitis delta virus (HDV) infection in Sub-Saharan Africa are ill-defined. The prevalence of HDV infection was determined in HIV/hepatitis B virus (HBV) co-infected individuals in rural Tanzania. METHODS: All hepatitis B virus (HBV)-infected adults under active follow-up in the Kilombero and Ulanga Antiretroviral Cohort (KIULARCO) were screened for anti-HDV antibodies. For positive samples, a second serological test and nucleic acid amplification were performed. Demographic and clinical characteristics at initiation of antiretroviral therapy (ART) were compared between anti-HDV-negative and positive patients. RESULTS: Among 222 HIV/HBV co-infected patients on ART, 219 (98.6%) had a stored serum sample available and were included in the study. Median age was 37 years, 55% were female, 46% had World Health Organization stage III/IV HIV disease, and the median CD4 count was 179 cells/mul. The prevalence of anti-HDV positivity was 5.0% (95% confidence interval 2.8-8.9%). There was no significant predictor of anti-HDV positivity. HDV could not be amplified in any of the anti-HDV-positive patients and the second serological test was negative in all of them. CONCLUSIONS: No confirmed case of HDV infection was found among over 200 HIV/HBV co-infected patients in Tanzania. As false-positive serology results are common, screening results should be confirmed with a second test.
dc.format.extent3 p.
dc.format.mimetypeapplication/pdf
dc.identifier.issn1201-9712
dc.identifier.pmid26996457
dc.identifier.urihttps://hdl.handle.net/2445/98687
dc.language.isoeng
dc.publisherElsevier Inc.
dc.relation.isformatofReproducció del document publicat a: http://dx.doi.org/10.1016/j.ijid.2016.03.011
dc.relation.ispartofInternational Journal of Infectious Diseases, 2016, vol. 46, p. 8-10
dc.relation.urihttp://dx.doi.org/10.1016/j.ijid.2016.03.011
dc.rightscc by-nc-nd (c) Winter et al., 2016
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/3.0/es/
dc.sourceArticles publicats en revistes (ISGlobal)
dc.subject.classificationVIH (Virus)
dc.subject.classificationVirus de l'hepatitis delta
dc.subject.otherHIV (Viruses)
dc.subject.otherHepatitis D (hepatitis delta)
dc.titleAbsence of hepatitis delta infection in a large rural HIV cohort in Tanzania
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:eu-repo/semantics/publishedVersion

Fitxers

Paquet original

Mostrant 1 - 1 de 1
Carregant...
Miniatura
Nom:
PIIS1201971216309985.pdf
Mida:
266.94 KB
Format:
Adobe Portable Document Format